NICE TA492: for untreated PL-L1-postive locally advanced or metastatic urothelial cancer in patients where cisplatin is unsuitable. (Decision date - January 2018).
NICE TA520: for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy. (Decision date - June 2018).
NICE TA525: for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy. (Decision date - July 2018).
NICE TA584: in combination for treating metastatic non-squamous non-small-cell lung cancer. (Decision date - July 2019).
NICE TA638: with carboplatin and etoposide for untreated extensive stage small cell lung cancer. (Decision date - August 2020).
NICE TA639: with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer. (Decision date - August 2020).
NICE TA666: with bevacizumab for treating advanced or unresectable hepatocellular carcinoma. (Decision date - January 2021).
NICE TA705: monotherapy for
untreated advanced non-small-cell lung cancer. (Decision date - July 2021).
NICE TA739: for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable. (Decision date - Nov 2021).
NICE TA823: for adjuvant treatment of resected
non-small-cell lung cancer. (Decision date - October 2022).
DNP:
NICE TA618 - with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer. (Terminated appraisal) (Decision date - February 2020).
NICE TA1047: (Terminated appraisal) Atezolizumab for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable (decision date April 2025)
Do Not Prescribe (DNP) Drug Classifications
6: Have NICE guidance that recommends they should not be used
Red Drug Classifications
1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
8. NHS England commissioned – to be used in line with NHSE commissioning intentions
